TY - JOUR

T1 - Perspectives in Immunotherapy

T2 - meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

AU - Ascierto, Paolo A.

AU - Avallone, Antonio

AU - Bhardwaj, Nina

AU - Bifulco, Carlo

AU - Bracarda, Sergio

AU - Brody, Joshua D.

AU - Buonaguro, Luigi

AU - Demaria, Sandra

AU - Emens, Leisha A.

AU - Ferris, Robert L.

AU - Galon, Jérôme

AU - Khleif, Samir N.

AU - Klebanoff, Christopher A.

AU - Laskowski, Tamara

AU - Melero, Ignacio

AU - Paulos, Chrystal M.

AU - Pignata, Sandro

AU - Ruella, Marco

AU - Svane, Inge Marie

AU - Taube, Janis M.

AU - Fox, Bernard A.

AU - Hwu, Patrick

AU - Puzanov, Igor

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.

AB - Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here.

KW - Biomarkers

KW - Checkpoint inhibitors

KW - Combination therapy

KW - Immunotherapy

KW - Tumor microenvironment

KW - Vaccine

U2 - 10.1186/s12967-022-03471-y

DO - 10.1186/s12967-022-03471-y

M3 - Journal article

C2 - 35672823

AN - SCOPUS:85131465855

VL - 20

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 257

ER -